Abvc Biopharma (ABVC) Revenue (2010 - 2025)

Abvc Biopharma (ABVC) has reported Revenue for 13 consecutive years, with $795950.0 the latest figure, recorded in Q3 2025.

• For the quarter ending Q3 2025, Revenue rose 104.47% year-over-year to $795950.0; the trailing twelve-month figure through Sep 2025 stood at $1.3 million (up 155.86% YoY), and the FY2025 full-year result was $31779.0, down 93.76% from the prior year.
• Revenue advanced to $795950.0 in Q3 2025 per ABVC's latest filing, from $1966.0 in the prior quarter.
• Across five years, Revenue topped out at $795950.0 in Q3 2025 and bottomed at -$37793.0 in Q4 2021.
• Historically, Revenue has averaged $163738.2 across 5 years, with a median of $42269.0 in 2022.
• The sharpest annual moves came in 2021 and 2024: Revenue sank 160.77% in 2021, then soared 2350.74% in 2024.
• Over 5 years, Revenue stood at -$37793.0 in 2021, then surged by 1658.47% to $588994.0 in 2022, then slumped by 99.63% to $2165.0 in 2023, then decreased by 9.19% to $1966.0 in 2024, then jumped by 40385.76% to $795950.0 in 2025.
• According to Business Quant data, Revenue over the past three periods registered $795950.0, $1966.0, and $389276.0 for Q3 2025, Q4 2024, and Q3 2024 respectively.